Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiency


NCTID NCT06422351 (View at clinicaltrials.gov)
Description
Development Status Active
Indication Pyruvate Kinase Deficiency
Disease Ontology Term DOID:0111077
Compound Name RP-L301
Sponsor Rocket Pharmaceuticals Inc.
Funder Type Industry
Recruitment Status
Not yet recruiting
Enrollment Count 10
Results Posted Not Available

Therapy Information


Target Gene/Variant PKLR
Therapy Type Gene transfer
Therapy Route Ex-vivo
Mechanism of Action Functional gene replacement
Route of Administration Intravenous
Drug Product Type Viral vector
Target Tissue/Cell
Delivery System Viral transduction
Vector Type PGK-coPRK-WPRE
Editor Type none
Dose 1 Dose range: 2.3E6 - 6.5E6 transduced CD34+ cells/kg
Dose 2
Dose 3
Dose 4
Dose 5

Study Record Dates


Current Stage Phase2
Submit Date 2024-05-15
Completion Date 2029-01
Last Update 2024-05-22

Participation Criteria


Eligible Age 8 Years - 55 Years
Standard Ages Child, Adult
Sexes Eligible for Study ALL

Locations


No.of Trial Sites 3
Locations United States,Spain

Regulatory Information


Has US IND True
FDA Designations Fast Track, Orphan Drug Designation, Regenerative Medicine Advanced Therapy
Recent Updates

Resources/Links